Last reviewed · How we verify
IV TXA
IV TXA (tranexamic acid) inhibits fibrinolysis by blocking plasminogen activation, thereby reducing bleeding.
IV TXA (tranexamic acid) inhibits fibrinolysis by blocking plasminogen activation, thereby reducing bleeding. Used for Acute hemorrhage and trauma, Perioperative blood loss reduction, Heavy menstrual bleeding.
At a glance
| Generic name | IV TXA |
|---|---|
| Sponsor | Massachusetts General Hospital |
| Drug class | Antifibrinolytic agent |
| Target | Plasminogen / Plasmin |
| Modality | Small molecule |
| Therapeutic area | Hematology / Hemostasis |
| Phase | FDA-approved |
Mechanism of action
Tranexamic acid is a competitive inhibitor of plasminogen and plasmin, which are enzymes responsible for breaking down fibrin clots. By preventing fibrin degradation, it stabilizes clots and reduces hemorrhage. It is commonly used intravenously in acute bleeding situations, trauma, and perioperative settings to minimize blood loss.
Approved indications
- Acute hemorrhage and trauma
- Perioperative blood loss reduction
- Heavy menstrual bleeding
Common side effects
- Thromboembolism (venous thromboembolism, myocardial infarction)
- Seizures
- Visual disturbances
- Nausea and vomiting
Key clinical trials
- The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies (PHASE3)
- Tranexamic Acid in Reducing Blood Loss in Patients With Pelvic Tumors Undergoing Hemipelvectomy Surgery (EARLY_PHASE1)
- Extended Oral Tranexamic Acid After Anterior Cruciate Ligament Reconstruction (PHASE4)
- The Effects of Tranexamic Acid on Joint Inflammation and Cartilage Health in Anterior Cruciate Ligament Injured Patients (PHASE2)
- Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children (PHASE3)
- Precision Use of TXA in Intracerebral Hemorrhage (NA)
- A Trial of a Hospital Policy of Tranexamic Acid Use to Reduce Transfusion in Major Non-cardiac Surgery (PHASE4)
- Effect of Intravenous and Topical Tranexamic Acid on Drain Output in Breast Reduction Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV TXA CI brief — competitive landscape report
- IV TXA updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI